Ali Merhe
Overview
Explore the profile of Ali Merhe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kryvenko O, Epstein J, Merhe A, Iakymenko O, De Almeida E Silva Junior R, Chanamolu D, et al.
Am J Clin Pathol
. 2024 Feb;
162(1):51-61.
PMID: 38412318
Objectives: There are 2 grading approaches to radical prostatectomy (RP) in multifocal cancer: Grade Group (GG) and percentage of Gleason pattern 4 (GP4%). We investigated whether RP GG and GP4%...
2.
de Almeida S Jr R, Thomas J, Mason M, Becerra M, Merhe A, Reis I, et al.
BJUI Compass
. 2023 Aug;
4(5):591-596.
PMID: 37636212
Objective: The study aims to identify the optimal 4Kscore thresholds to determine the need for a prostate biopsy when multiparametric magnetic resonance imaging (MRI) (mpMRI) is negative or indeterminate. Materials...
3.
Hougen H, Merhe A, Punnen S
Eur Urol Focus
. 2022 Jun;
8(4):893-894.
PMID: 35691842
For patients with clinical suspicion of prostate cancer, liquid biomarkers are the next best test because of their accessibility, objectiveness, and noninvasive nature. A highly sensitive cutoff for these biomarkers...
4.
Bahmad H, Demus T, Moubarak M, Daher D, Alvarez Moreno J, Polit F, et al.
Med Sci (Basel)
. 2022 Feb;
10(1).
PMID: 35225948
Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease...
5.
Hout M, Merhe A, Heidar N, El-Asmar J, Wazzan W, Bachir B, et al.
Arch Ital Urol Androl
. 2021 Dec;
93(4):385-388.
PMID: 34933522
Background: The aim of our study was to evaluate the outcome of active surveillance (AS) for prostate cancer for a cohort of patients at our institution. Methods: A total of...
6.
Kryvenko O, Iakymenko O, De Lima Guido L, Bhattu A, Merhe A, Mouzannar A, et al.
Arch Pathol Lab Med
. 2021 Nov;
146(8):1012-1017.
PMID: 34739539
Context.—: Prostatic ductal adenocarcinoma (PDA) has historically been considered to be an aggressive subtype of prostate cancer. Objective.—: To investigate if PDA is independently associated with worse biochemical recurrence (BCR)-free...
7.
Khauli M, Heidar N, Degheili J, Hakam N, Al-Moussawy M, Shahait M, et al.
Urol Ann
. 2021 Jul;
13(2):130-133.
PMID: 34194138
Introduction: Renal cell carcinoma (RCC) has various histopathological tumor subtypes which have a significant implication on the oncological outcome of these patients. We aimed to evaluate the distribution of RCC...
8.
Heidar N, El-Doueihi R, Merhe A, Ramia P, Bustros G, Yacoubian A, et al.
Urologia
. 2021 May;
89(1):64-69.
PMID: 33985388
Introduction: Prostate cancer (PCa) staging is an integral part in the management of prostate cancer. The gold standard for diagnosing lymph node invasion is a surgical lymphadenectomy, with no superior...
9.
Merhe A, Heidar N, Hout M, Bustros G, Mailhac A, Tamim H, et al.
Arab J Urol
. 2020 Oct;
18(3):136-141.
PMID: 33029422
Objective: To perform a time-to-complication analysis for radical prostatectomy (RP) and computing risk factors for these complications, as RP is established as a first-line treatment for localised prostate cancer with...
10.
Merhe A, Hout M, Heidar N, El-Asmar J, Jaafar R, Mailhac A, et al.
Arab J Urol
. 2020 Oct;
18(2):72-77.
PMID: 33029410
Objectives: To assess the safety and surgical outcomes of radical prostatectomy (RP) when looking at age as an independent risk factor of perioperative mortality and morbidity. Patients And Methods: A...